The remaining trials incorporated secondary endpoints assessing intracranial response and/or time to intracranial progression, including trials such as ARROW (pralsetinib) (35) and LIBRETTO-001 (selpercatinib) (36) for RET rearranged NSCLC, HER2CLIMB (tucatinib) (39) for HER2 positive breast cancer and ALKA/STARTRK-1/STARTRK-2 (entrectinib) (40, 41) for NTRK rearranged solid tumors and ROS1 rearranged NSCLC. Here, ERBB2 is linked to non-small cell lung carcinoma.